skip to main content

Hepatitis B — SCE Infectious Diseases MCQ

Instant feedback + full explanation. One question, done properly.

HardHepatitisHepatitis BSCE Infectious Diseases

A 35-year-old woman has HBeAg-negative chronic hepatitis B, HBV DNA 15,000 IU/mL, ALT 85 U/L and compensated F2 liver disease. Pregnancy is excluded and she has no contraindication to interferon. Which first-line treatment follows NICE CG165?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Peginterferon alfa-2a for 48 weeks

Her raised ALT, HBV DNA above 2,000 IU/mL and fibrosis indicate active HBeAg-negative chronic hepatitis B requiring treatment. NICE CG165 offers a 48-week course of peginterferon alfa-2a first-line in compensated HBeAg-negative disease when suitable; tenofovir disoproxil or entecavir are the second-line sequence if HBV DNA remains detectable.

Reference: NICE CG165: https://www.nice.org.uk/guidance/cg165/chapter/Recommendations